



## CURRICULUM VITAE

Ahmed Kaseb, MD

### PRESENT TITLE AND AFFILIATION

#### Primary Appointment

Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### CITIZENSHIP

United States

### OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center  
1600 Holcombe Boulevard, Unit Number: 426  
Houston, TX 77030  
Room Number: FC10.3064  
Phone: 713-792-2828  
Fax: 713-563-0541  
Email: akaseb@mdanderson.org

### EDUCATION

#### Degree-Granting Education

Cairo University School of Medicine, Cairo, Egypt, MBBS, 1996, Medicine

#### Postgraduate Training

Clinical Internship, Medicine, Cairo University Hospitals, Cairo, Egypt, 3/1997–2/1998

Externship, Internal Medicine, Michigan State University, East Lansing, MI,  
12/1998–6/1999

Research Fellowship, Pediatrics and Human Genetics, University of Michigan, Ann  
Arbor, MI, 9/1999–6/2001

Internal Medicine Residency, Internal Medicine, Wayne State University/Detroit Medical  
Center, Sinai-Grace Hospital, Detroit, MI, 7/2001–6/2004

Internal Medicine Staff Physician, Internal Medicine, Henry Ford Hospital, Detroit, MI,  
7/2004–6/2005

Medical Oncology Fellow, Internal Medicine, Henry Ford Hospital, Detroit, MI,  
7/2005–6/2007

### CREDENTIALS

#### Board Certification

American Board of Internal Medicine  
American Board of Medical Oncology  
American Board of Medical Quality

## **Licensures**

### **Active**

State of Texas Medical License

## **Administrative Appointments/Responsibilities**

**Editor-in-Chief:** Journal of Hepatocellular Carcinoma

**PI and Director:** The University of Texas MD Anderson Cancer Center SPORE in HCC

**Member:** NIH/NCI Liver Cancer/HCC Working Group

**Invited as a Co-Chair:** Systemic Therapy for Advanced Hepatocellular Carcinoma Guideline Panel, American Society of Clinical oncology: 2/2018.

**Chair, Steering Committee:** Hepatocellular Carcinoma International Biomarkers Assessment Consortium (HIBAC): with MD Anderson Cancer Center sister institutions network, China, Korea, Thailand, Turkey, Egypt, and Brazil.

**Member:** Educational Committee, International Liver Cancer Association (ILCA)

**Member, Executive Committee, Harris County Medical Society:** Houston, Texas: 2017-2018

**Member, Executive Committee, Houston Academy of Medicine:** Houston, Texas: 2017-2018

**Co-Chair, Senatorial district 11, Texas Medical Association Political Action Committee (TexPAC):** 2017-curr

**Chair, Council of International and Affiliated Medical Societies:** Harris County Medical Society, Houston, Texas: 2017/2018

**Member:** Clinical Research Committee, The University of Texas MD Anderson Cancer Center, Houston, TX: 2013-2018

**Member:** Institutional Board Review, The University of Texas MD Anderson Cancer Center, Houston, TX: 2019-

**Member:** Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, Houston, TX: 2013-2016

**Disease Site Liaison:** for the Gastrointestinal Center: International Patient Center, The University of Texas MD Anderson Cancer Center, Houston, TX: 2009-2019

## **Other Appointments/Responsibilities**

**Founder and Director,** Hepatocellular Carcinoma Interdisciplinary Research Group (HIRG), MD Anderson Cancer Center, Houston, TX, 2007–present

**Founder and Director,** Black Seed Research Group, MD Anderson cancer Center,

Houston, TX, 2007–present

**Leader**, Comprehensive Cancer Control Initiative (HCC), MD Anderson Cancer Center:  
**goal:** decreasing incidence and mortality of HCC in Harris County residents, which involved community leadership meetings and fundraising efforts

**Scoutmaster**, Boy Scouts of America, Houston, Texas

**Research Support/Consultantships/Advisory Boards**

Bayer/Onyx Health Care Pharmaceuticals, BMS Pharmaceuticals, Merck, Genentech/Roche Pharmaceuticals, and Exelixis

**Military or Other Governmental Service**

N/A

**Institutional Committee Activities**

Cancer Center Faculty Senate, Elected Member: 2008-2011

Leader, Comprehensive Cancer Control Initiative (HCC): 2009-Curr

Clinical Research Committee: 2013-2019

Credentials Committee of the Medical Staff: 2012-2016

**HONORS AND AWARDS**

**The Egyptian Government Award**, Egypt, 1990

**ACP Merit Award**, American College of Physicians, 2004

**Best Ambulatory Resident Award**, Wayne State University, Detroit, Michigan, 2004

**ACP Merit Award**, American College of Physicians, 2005

**ASCO Foundation Merit Award**, American Society of Clinical Oncology, 2006

**Basic Research Presentation Merit Award**, 13th Annual Research Forum of Henry Ford Health System, Detroit, Michigan, 2006

**MD Anderson Faculty Recognition Award:** for productivity and quality contributions to the University of Texas MD Anderson Cancer Center: annually since 2011

**RESEARCH**

**Active Grants, Contracts and protocols (past 5 years)**

**Funded**

**Principal Investigator and Director**, The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma.

**1P50CA217674-01A1: Kaseb AO and Beretta L (PIs)** 2019-2024, \$12,137,335.00

**Principal Investigator and Admin Core Director**,

Overall SPORE clinical PI, Director, Administrative Core director and Project 1 leader (clinical), Project 2 leader (clinical) and co-Chair, Executive Committee.

**Principal Investigator**, An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients with Resectable and Potentially Resectable HCC (CA209-956) (2016-2020). Goal: evaluate perioperative immunotherapy in resectable HCC.

**Principal Investigator**, A Phase I/II to Investigate the Safety, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (Pembrolizumab) in Advanced Hepatocellular Carcinoma in subjects who progressed or were intolerant to sorafenib. (2016-2018). Goal: evaluate anti-PD1 immune correlates in advanced HCC

**Principal Investigator**, A Phase I/II study of pembrolizumab plus Zepatier in Advanced

Hepatocellular Carcinoma in subjects with hepatitis C who progressed or were intolerant to sorafenib. (2018-2020). Goal: evaluate anti-PD1 immune correlatives in advanced HCC related to HCV

**Principal Investigator**, A Phase I/II study of pembrolizumab plus lenvatinib in Advanced Hepatocellular Carcinoma. (2018-2020). Goal: evaluate anti-PD1 combination with anti-VEGF immune correlatives in advanced HCC

**Principal Investigator**, Phase I trial evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with hepatocellular carcinoma (ACTengine IMA202-101) (2018-2020). Goal: evaluate role of T cell therapy with mammalian cell targets in advanced HCC

**Principal Investigator**, A Phase II study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C. (2013-2018). Goal: evaluate role of combined sorafenib with radio-embolization in advanced HCC

**Principal Investigator**, A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (2018-0074) (2018-2020). Goal: evaluate role of combined anti-PDL1 with anti-VEGF in advanced HCC compared to sorafenib alone.

**Principal Investigator**, A Phase 1 Trial of ABT-263 (Navitoclax), a Bcl-2 inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors. (NCI9608) (2018-2020). Goal: evaluate role of combined sorafenib plus anti-Bcl2 therapy in advanced HCC

**Principal Investigator**, Phase I Open Label Study Evaluating Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFP<sup>c332T</sup>) in HLA-A2 Positive Subjects with Advanced HCC (AdaptImmune) (2018-2020). Goal: evaluate role of T cell therapy using AFP as a target in advanced HCC.

Principal Investigator, **Bayer Inc. Research Grant**: HCC Virtual Tumor Board (04/01/2018-03/31/2020)

### Completed Grants, Contracts and protocols

Principal Investigator, **R21 NIH grant #R21CA190945-01A1**, Novel Point-of-Care Tool to Predict Response to Sorafenib in HCC, 11/30/2015-11/29/2018

Principal Investigator, **R21 NIH grant #1R21CA170035-01**: Integrating plasma IGF-1 into novel classification of hepatocellular carcinoma, 07/09/2012-06/30/2014

Principal Investigator, **MDACC Sister Institution Network Funding**: Novel point-of-care tool to predict response to sorafenib in hepatocellular carcinoma, 04/01/2015-03/31/2018

**Principal Investigator**, A Phase II Trial of Erlotinib plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy, 2009-0260, (2011–2015)

**Principal Investigator**, A Phase III Randomized, Placebo Controlled, Double-Blind Trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First-line systemic Treatment of Hepatocellular Carcinoma (HCC), SEARCH trial. (2009–2012)

**Principal Investigator**, A Randomized, Double-Blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy of Trans-Arterial Chemo Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma, CA182-037, 2009–2012

ID00-083

07/15/2011-09/30/2013

Glypican in Hepatocellular Carcinoma

Bayer/ Onyx 08/16/2011-08/15/2012  
 Prognostic Factors in Hepatocellular Carcinoma

MDACC-2009-0556 Crane (PI) 2011-2014  
 P01 supported: Phase II study of proton beam irradiation for the treatment of unresectable HCC and cholangiocarcinoma  
 Role: Co-Principal Investigator

N01-CM-62202 09 Chris Crane (PI) 01/01/2006-12/31/2010  
 Early Therapeutics Development with Phase II Emphasis (PP-20)  
 Role: Co-Principal Investigator

MDACC-2006-0851 **Kaseb (PI)** 2006-2009  
 A Phase II Study Trastuzumab (NSC 688097) in Her2/neu Positive Cancer of the Gallbladder or Biliary Tract (NCI 7756)  
 Role: Principal Investigator

MDACC-2006-0566. **Kaseb (PI)** 2006-2009  
 A Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Second Line Therapy for Patients with Advanced Primary Cancers of the Liver, including Hepatocellular Carcinoma (HCC) and Carcinoma of the Gallbladder or Biliary Tract (BTC) (P01-05-23).  
 Role: Principal Investigator

MDACC-2008-0396 Vauthey (PI) 2009-2010  
 Co-Principal Investigator, A Phase III Randomized, Double-Blind, Placebo Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma after Surgical Resection or Local Ablation.  
 Role: Co-PI

2005-0881 Krishnan (PI) 2005-11/19/2009  
 A Phase I Study of Proton Radiotherapy and Bevacizumab for Primary Liver Tumors.  
 Role: Co-Principal Investigator

2008--0396 J-N Vauthey (PI) 2008-2010  
 A Phase III Randomized, Double-Blind, Placebo Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma after Surgical Resection or Local Ablation.  
 Role: Co-Principal Investigator

2006-0053 Murthy (PI) 2006-10/28/2009  
 A Phase II Study of Yttrium-90 Microspheres (SIR-Spheres) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma.  
 Role: Co-Principal Investigator

**Grant Reviewer/Service on Study Sections**

Liver Cancer Study Section, Department of Defense (DOD), NCI

**PUBLICATIONS****Complete List of Published Work in My Bibliography:**

<https://www.ncbi.nlm.nih.gov/pubmed/?term=kaseb+a>

**Select Peer-Reviewed Original Research Articles**

1. Yang H, Yang K, Khafagi A, Tang Y, Carey TE, Opipari AW, Lieberman R, Oeth PA, Lancaster W, Klinger HP, **Kaseb AO**, Metwally A, Khaled H, Kurnit DM. Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. *Proc Natl Acad Sci U S A* 102(21):7683-8, 5/2005. PMID: PMC1140403.
2. Bai VU, **Kaseb A**, Tejwani S, Divine GW, Barrack ER, Menon M, Pardee AB, Reddy GP. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. *Proc Natl Acad Sci U S A* 104(7):2343-8, 2/2007. e-Pub 2/2007. PMID: PMC1892964.
3. **Kaseb AO**, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. *Cancer Res* 67(16):7782-8, 8/2007.
4. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, **Kaseb A**, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. *Int J Cancer* 123(8):1883-91, 10/2008. PMID: PMC2673571.
5. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Lin E, **Kaseb A**, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. *J Clin Oncol* 27(6):843-50, 2/2009. e-Pub 1/2009.
6. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, **Kaseb A**, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. *J Hepatol* 50(2):334-41, 2/2009. e-Pub 10/2008. PMID: PMC2658718.
7. Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, **Kaseb AO**, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. *Surgery* 145(4):399-405, 4/2009.
8. Hassan MM, **Kaseb A**, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. *Hepatology* 49(5):1563-70, 5/2009.
9. Banerjee S, **Kaseb AO**, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. *Cancer Res* 69(13):5575-83, 7/2009. e-Pub 6/2009.
10. **Kaseb AO**, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. *Cancer* 115(21):4895-906, 2009, 11/2009.
11. Hassan MM, Curley SA, Li D, **Kaseb A**, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. *Cancer* 116(8):1938-46, 4/2010.
12. **Kaseb AO**, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for

- clinical trials. *Cancer*. e-Pub 12/2010. PMID: PMC3066286.
13. Skinner HD, Sharp HJ, **Kaseb AO**, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. *Acta Oncol*. e-Pub 7/2011.
  14. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, **Kaseb AO**, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. *Invest New Drugs* 29(4):694-9, 8/2011. e-Pub 1/2010.
  15. **Kaseb AO**, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A, Morris JS. I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score. *Oncology* 80(5-6):373-381. e-Pub 8/2011.
  16. **Kaseb AO**, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. *J Clin Oncol* 29(29):3892-9, 10/2011. e-Pub 9/2011. PMID: PMC3189091.
  17. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, **Kaseb A**, Park YN, Wang XW, Thorgeirsson SS, Lee JS. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. *Hepatology*. e-Pub 11/2011.
  18. **Kaseb AO**, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial. *Oncology* 82(2):67-74. e-Pub 2/2012.
  19. Mahale P, **Kaseb AO**, Davila M, Torres HA. The Effect of Transcatheter Arterial Chemoembolization on Hepatitis C viremia. *Oncologist*. 2012;17(9):e21-3.
  20. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, **Kaseb AO**, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. *Oncotarget*. 2013 Jan 27.
  21. Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. *World J Hepatol*. 2013 Jun 27;5(6):332-5.
  22. Shindoh J, Kaseb A, Vauthey JN. Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy. *Liver Cancer*. 2013 Jan;2(1):47-54. Review.
  23. Myers AI, Zhang YP, Kramer MA, Bornmann WG, **Kaseb A**, Yang P, and Tran HT. A Practical Synthesis and X-ray Crystallographic Analysis of Dithymoquinone, a Photodimer of Thymoquinone. *Letters in Organic Chemistry*, 2012(9):762-766.
  24. Frenette CT, Boktour M, Burroughs SG, **Kaseb A**, Aloia TA, Galati J, Gaber AO, Monsour H Jr, Ghobrial RM. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. *Transpl Int*. 2013 Jul;26(7):734-9.
  25. Sahin HI, **Kaseb A**. A comment on 'A morpho-molecular prognostic model for hepatocellular carcinoma'. *Br J Cancer*. 2013 Feb 19;108(3):740.
  26. Hassan MM, **Kaseb A**, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. *Mol Carcinog*. 2013 Nov;52 Suppl 1:139-47.
  27. **Kaseb AO**, Shindoh J, Patt YZ, Roses R, Zimmiti G, Lozano R, Hassan M, Hassabo H,

- Curley S, Aloia T, Abbruzzese JL, and Vauthey JN. Modified Cisplatin/Interferon  $\alpha$ -2b/Doxorubicin/5-Fluorouracil (PIAF) Chemotherapy in Patients With No Hepatitis or Cirrhosis Is Associated With Improved Response Rate, Resectability, and Survival of Initially Unresectable Hepatocellular Carcinoma. *Cancer*. 2013 Sep 15;119(18):3334-42.
28. **Kaseb AO**, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma. *Oncology*. 2013 Sep 19;85(4):197-203.
  29. **Kaseb AO**, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M, Aloia TA, Curley S, Abbruzzese JL, and Hassan MM. Reassessing Hepatocellular Carcinoma Staging in a Changing Patient Population. *Oncology*. 2014 Jan 8;86(2):63-71.
  30. Faria SC, Szklaruk J, **Kaseb AO**, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. *Abdom Imaging*. 2014 Apr 3.
  31. Das P, Abboud MT, Haque W, Javle M, **Kaseb A**, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. *Pract Radiat Oncol*. 2013 Oct-Dec;3(4):344-8.
  32. Ganeshan D, Szklaruk J, Kundra V, **Kaseb A**, Rashid A, Elsayes KM. *AJR Am J Roentgenol*. Imaging features of fibrolamellar hepatocellular carcinoma. 2014 Mar;202(3):544-52. Review. Erratum in: *AJR Am J Roentgenol*. 2014 Apr;202(4):933.
  33. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. *Oncotarget*. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. 2014 May 30;5(10):3012-22.
  34. **Kaseb AO**, Xiao, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia TA, Conrad C, Curley S, Vierling J, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, and Morris JS. Development and validation of an IGF-1 score to assess hepatic reserve in hepatocellular carcinoma. *J of Natl Cancer Inst*. 2014 May 9;106(5).
  35. Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, **Kaseb A**, Shroff RT. Second-line systemic treatment for advanced cholangiocarcinoma. *J Gastrointest Oncol*. 2014 Dec;5(6):408-413.
  36. Janku F, **Kaseb AO**, Tsimberidou AM, Wolff RA, Kurzrock R. *Oncotarget*. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. 2014 May 30;5(10):3012-22.
  37. Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, **Kaseb A**, Kim BH, Kim WB, Yeon JE, Byun KS, Chu IS, Kim SS, Wang XW, Thorgeirsson SS, Luk JM, Kang KJ, Heo J, Park YN, Lee JS. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. *PLoS Med*. 2014 Dec 23;11(12):e1001770.
  38. Odisio BC, Ashton A, Yan Y, Wei W, **Kaseb A**, Wallace MJ, Vauthey JN, Gupta S, Tam AL. Transarterial Hepatic Chemoembolization with 70-150  $\mu$ m Drug-Eluting Beads: Assessment of Clinical Safety and Liver Toxicity Profile. *J Vasc Interv Radiol*. 2015 Jul;26(7):965-71.
  39. Bupathi M, **Kaseb AO**, Bern-Stram F, Naing A. Hepatocellular Carcinoma: Where There Is Unmet Need Molecular Oncology. *Mol Oncol*. 2015 Oct;9(8):1501-9.
  40. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. *J Hematol Oncol*. 2015 May 29;8(1):58



41. Subbiah IM, Falchook GS, **Kaseb AO**, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. *Oncotarget*. 2015 Jun 23.
42. Abdel-Wahab, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Hassabo H, Shalaby A, Essa HH, Mossad E, Raghav K, Rashid A, Wolff, R, Morris JS, Amin HM, **Kaseb AO**. Validation of an IGF-CTP Scoring System for Assessing Hepatic Reserve in Egyptian Patients with Hepatocellular Carcinoma. *Oncotarget*, 2015 Aug 28;6(25):21193-207.
43. Abdel-Wahab, R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, and **Kaseb AO**. Type I insulin-like growth factor as a liver reserve assessment tool in HCC. *J of HCC*. 2015 Sep;2;131—142.
44. Torres HA, Mahale P, Blechacz B, Miller E, **Kaseb A**, Herlong HF, Fowler N, Jiang Y, Raad II, Kontoyiannis DP. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. *J Natl Compr Canc Netw* 13(1):41-50, 1/2015. PMID: 25583768.
45. Mohamed A, Chenna A, Abdelfatah M, Sanjay J, Mohammad MK, Saber I, Kauh J, Elhammali B, **Kaseb A**. Microvessel Density Analysis in Patients with Viral Hepatitis-Related Hepatocellular Carcinoma. *J Gastrointest Cancer*. e-Pub 2/2015. PMID: 25645584.
46. Hassan MM, Abdel-Wahab R, **Kaseb A**, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. *Gastroenterology*. e-Pub 3/2015. PMID: 25836985.
47. Mahale P, **Kaseb AO**, Hassan MM, Torres HA. Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection. *Dig Liver Dis* 47(4):348-9, 4/2015. e-Pub 12/2014. PMID: 25563811.
48. Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick GE, **Kaseb AO**, Shi P, Amin HM. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma. *Mol Cancer* 14(1):324, 12/2015. e-Pub 2/2015. PMID: 25777566.
49. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, **Kaseb AO**, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. *J Clin Oncol* 34(3):219-26, 1/2016. e-Pub 10/2015. PMID: PMC4980564.
50. Jauch SF, Morris VK, Jensen CT, **Kaseb AO**. Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report. *Pancreatology* 16(1):153-6, Jan-Feb, 1/2016. e-Pub 9/2015. PMID: 26456669. Impact Factor
51. Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, **Kaseb A**, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. *Clin Cancer Res* 22(5):1256-64, 3/2016. e-Pub 10/2015. PMID: 26459179.
52. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, **Kaseb AO**, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. *Oncotarget*. e-Pub 8/2016. PMID: 27589687.
53. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, **Kaseb A**, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary cancer: Utility of next-generation sequencing for

- clinical management. *Cancer*. e-Pub 9/2016. PMID: 27622582.
54. Yamashita S, Vauthey JN, **Kaseb AO**, Aloia TA, Conrad C, Hassan MM, Passot G, Raghav KP, Shama MA, Chun YS. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. *J Gastrointest Surg* 20(10):1725-31, 10/2016. e-Pub 7/2016. PMID: 27456016.
  55. Economides MP, Mahale P, Kyvernitakis A, Turturro F, Kantarjian H, Naing A, Hosry J, Shigle TL, **Kaseb A**, Torres HA. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. *Aliment Pharmacol Ther* 44(11-12):1235-1241, 12/2016. e-Pub 10/2016. PMID: 27730654.
  56. Atta MM, Atta HM, Gad MA, Rashed LA, Said EM, Hassanien Sel-S, **Kaseb AO**. Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients. *J Hepatocell Carcinoma* 3:19-24, 2016. e-Pub 6/2016. PMCID: PMC4994801.
  57. Abdelsalam ME, Murthy R, Avritscher R, Mahvash A, Wallace MJ, **Kaseb AO**, Odisio BC. Minimally invasive image-guided therapies for hepatocellular carcinoma. *J Hepatocell Carcinoma* 3:55-61, 2016. e-Pub 10/2016. PMCID: PMC5067062.
  58. **Kaseb AO**, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. *Onco Targets Ther* 9:773-80, 2016. e-Pub 2/2016. PMCID: PMC4760665.
  59. Mitchell J, Tinkey PT, Avritscher R, Van Pelt C, Eskandari G, Konnath George S, Xiao L, Cressman E, Morris JS, Rashid A, **Kaseb AO**, Amin HM, Uthamanthil R. Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. *Oncology* 91(2):90-100, 2016. e-Pub 6/2016. PMID: 27305144.
  60. Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, **Kaseb AO**. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. *J Hepatocell Carcinoma*. 2016 Feb 5;3:1-7. e-Pub 2/2016. PMID: 27574586.
  61. **Kaseb AO**, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. *Oncotarget*. e-Pub 9/2016. PMID: 27655712.
  62. Vishwamitra D, George SK, Shi P, **Kaseb AO**, Amin HM. Type I insulin-like growth factor receptor signaling in hematological malignancies. *Oncotarget*. e-Pub 9/2016. PMID: 27661006.
  63. Torres HA, Vauthey JN, Economides MP, Mahale P, **Kaseb A**. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. *J Hepatol* 65(4):862-4, 10/2016. e-Pub 5/2016. PMID: 27255582.
  64. Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, Chun YS, Aloia TA, Tao R, **Kaseb A**, Javle M, Crane CH, Vauthey JN. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. *Cancer*. 2017 Apr 15;123(8):1354-1362.
  65. Kutlu OC, Chan JA, Aloia TA, Chun YS, **Kaseb AO**, Passot G, Yamashita S, Vauthey JN, Conrad C. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. *Cancer*. 2017 Jan 13.
  66. Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, **Kaseb AO**. Refining prognosis in patients with hepatocellular carcinoma through

- incorporation of metabolic imaging biomarkers. *Eur J Nucl Med Mol Imaging*. 2016 Dec 12.
67. Ali MA, Lacin S, Abdel-Wahab R, Uemura M, Hassan M, Rashid A, Duda DG, **Kaseb AO**. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? *Onco Targets Ther*. 2017 Mar 3;10:1403-1412. Review.
  68. Rogers JE, Bolonesi RM, Rashid A, Elsayes KM, Elbanan MG, Law L, **Kaseb A**, Shroff RT. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. *J Gastrointest Oncol*. 2017 Apr;8(2):347-351.
  69. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, **Kaseb AO**. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol*. 2017 Nov;15(11):1791-1799.
  70. Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, **Kaseb A**, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. *CA Cancer J Clin*. 2017 Sep;67(5):411-431. Review.
  71. Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, **Kaseb AO**. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. *Oncology*. 2017;93(4):233-242.
  72. Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, **Kaseb AO**, Cohen L, Bruera E. A Double-Blind, Randomized, Placebo-Controlled Trial of *Panax Ginseng* for Cancer-Related Fatigue in Patients With Advanced Cancer. *J Natl Compr Canc Netw*. 2017 Sep;15(9):1111-1120.
  73. **Kaseb AO**. Grant, deny, or reassess the role of yttrium-90 in hepatocellular carcinoma? *Lancet Oncol*. 2017 Dec;18(12):1560-1561. Epub 2017 Oct 26. PMID: 29107680
  74. Odisio BC, **Kaseb AO**. Anti-angiogenic therapy in the setting of TACE: an elusive synergy? *Lancet Gastroenterol Hepatol* 3(1):5-6, 1/2018. e-Pub 10/2017. PMID: 28988686.
  75. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, **Kaseb AO**, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM, Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC). Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. *Lancet Gastroenterol Hepatol* 3(5):337-348, 5/2018. e-Pub 3/2018. PMID: 29548617.
  76. **Kaseb AO**. Editorial: charting the future of hepatocellular carcinoma publications. *J Hepatocell Carcinoma* 5:51-54, 2018. e-Pub 5/2018. PMCID: PMC5947843.
  77. Dandachi D, Hassan M, **Kaseb A**, Angelidakis G, Torres HA. Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer. *J Hepatocell Carcinoma* 5:81-86, 2018. e-Pub 8/2018. PMCID: PMC6080868.
  78. Hosry J, Angelidakis G, **Kaseb A**, Jiang Y, Torres HA. Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study. *Clin Infect Dis*. 2018 May 15. Doi: 10.1093/cid/ciy387. PMID: 30124786
  79. Khalaf AM, Fuentes D, Morshid AI, Burke MR, **Kaseb AO**, Hassan M, Hazle JD, Elsayes KM. Role of Wnt/b-catenin signaling in hepatocellular carcinoma, pathogenesis, and

- clinical significance. *J Hepatocell Carcinoma*. 2018 June 27;5:61-73. Doi: 10.2147/JHC.S156701. eCollection 2018. Review. PMID: 29984212
80. Ganeshan D, Szklaurk J, **Kaseb A**, Kattan A, Elsayes KM. Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. *Abdom Radio (NY)*. 2018 June 13. Doi: 10.1007/s00261-018-1657-2. PMID: 29948061
81. Niekamp A, Abdel-Wahab R, Kuban J, Odisio BC, Mahvash A, Hassan MM, Qayyum A, **Kaseb A**, Sheth RA. Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-directed Therapies in Hepatocellular Carcinoma. *J Clin Med*. 2018 Apr 14;7(4). pii: E83. doi:10.3390/jcm7040083. PMID: 29661994
82. Holliday EB, Tao R, Brownlee Z, Das P, Krishnan S, Taniguchi C, Minsky BD, Herman JM, **Kaseb A**, Raghav K, Conrad C, Vauthey JN, Aloia TA, Chun YS, Crane CH, Koay EJ. Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. *Clin Transl Radiat Oncol*. 2017 Jun 7;4:39-45. Doi: 10.1016/j.ctro.2017.04.003. eCollection 2017 Jun. PMID: 29594206
83. Gingold JA, Zhu D, Lee DF, **Kaseb A**, Chen J. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. *Trends Mol Med*. 2018 Apr;24(4):395-411. doi: 10.1016/j.molmed.2018.02.006. Epub 2018 Mar 9. Review. PMID: 29530485
84. Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, **Kaseb A**, Raad II, Granwehr BP. Sofosbuvir-Based Therapy in Hepatitis C Virus-infected Cancer Patients: A Prospective Observational Study. *Am J Gastroenterol*. 2018 Nov 8. PMID: 30410039

85. Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, **Kaseb A**, Mahvash A. Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry. *Int J Radiat Oncol Biol Phys*. 2018 Oct 1;102(2):451-461. PMID: 30191875
86. Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, **Kaseb A**, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. *Cancer Med*. 2018 Oct;7(10):4880-4892. doi: 10.1002/cam4.1734. Epub 2018 Aug 27. PMID: 30152073
87. Hosry J, Angelidakis G, **Kaseb A**, Jiang Y, Torres HA. Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study.. *Clin Infect Dis*. 2018 Oct 30;67(10):1635-1636. doi: 10.1093/cid/ciy387. PMID: 30124786
88. Dandachi D, Hassan M, **Kaseb A**, Angelidakis G, Torres HA. Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer. *J Hepatocell Carcinoma*. 2018 Aug 2;5:81-86. doi: 10.2147/JHC.S164568. eCollection 2018. PMID: 30123783
89. Khalaf AM, Fuentes D, Morshid AI, Burke MR, **Kaseb AO**, Hassan M, Hazle JD, Elsayes KM. Role of Wnt/ $\beta$ -catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. *J Hepatocell Carcinoma*. 2018 Jun 27;5:61-73. Review. PMID: 29984212
90. Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. Ganeshan D, Szklaruk J, **Kaseb A**, Kattan A, Elsayes KM. *Abdom Radiol (NY)*. 2018 Dec;43(12):3340-3348. doi: 10.1007/s00261-018-1657-2. PMID: 29948061
91. Editorial: charting the future of hepatocellular carcinoma publications. **Kaseb AO**. *J Hepatocell Carcinoma*. 2018 May 8;5:51-54. doi: 10.2147/JHC.S159650. eCollection 2018. PMID: 29774205
92. Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma. Niekamp A, Abdel-Wahab R, Kuban J, Odisio BC, Mahvash A, Hassan MM, Qayyum A, **Kaseb A**, Sheth RA. *J Clin Med*. 2018 Apr 14;7(4). pii: E83. doi: 10.3390/jcm7040083. PMID: 29661994
93. Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Holliday EB, Tao R, Brownlee Z, Das P, Krishnan S, Taniguchi C, Minsky BD, Herman JM, **Kaseb A**, Raghav K, Conrad C, Vauthey JN, Aloia TA, Chun YS, Crane CH, Koay EJ. *Clin Transl Radiat Oncol*. 2017 Jun 7;4:39-45. doi: 10.1016/j.ctro.2017.04.003. eCollection 2017 Jun. PMID: 29594206
94. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, **Kaseb AO**, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM; Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC). Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. *Lancet Gastroenterol Hepatol*. 2018 May;3(5):337-348. *Lancet Gastroenterol Hepatol*. 2018 Jun;3(6):e3. PMID: 29548617
95. **Kaseb AO**, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey J-N, Alisson JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. *Cancer Immunology Research* 2019 Jul 9. DOI: 10.1158/2326-6066.
96. **Kaseb, AO**, Sanchez N, Sen S, Kelley RK, Tan B, Bocobo AG, Lim HC, Abdel-Wahab R, Uemura M, Qiao W, Xiao L, Morris J, Amin HA, Hassan MM, Banks KC, Lanman RB, Talasaz AA, Mills-Shaw KR, Wolff R, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R.

Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA. *Clin Cancer Res.* 2019, Jul 30. DOI: 10.1158/1078-0432.

### Invited Articles

1. Bupathi M, **Kaseb AO**, Janku A. Angiopoietin-2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. *Onco Targets Ther.* 2014 Oct 20;7:1927-32.
2. Faria SC, Szklaruk J, **Kaseb AO**, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. *Abdom Imaging.* 2014 Oct;39(5):1070-87.
3. Ganeshan D, Szklaruk J, Kundra V, **Kaseb A**, Rashid A, Elsayes KM. *AJR Am J Roentgenol.* Imaging features of fibrolamellar hepatocellular carcinoma. 2014 Mar;202(3):544-52. Review. Erratum in: *AJR Am J Roentgenol.* 2014 Apr;202(4):933.
4. **Kaseb AO**, Abaza YM, Roses RE. Multidisciplinary management of hepatocellular carcinoma. *Recent Results Cancer Res.* 2013;190:247-59.
5. **Kaseb AO.** The Top 5 Future Clinical Trials in Hepatocellular Carcinoma. *Hepatic Oncology*, 2015 (In Submission)
6. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Janku F, **Kaseb AO**, Tsimberidou AM, Wolff RA, Kurzrock R. *Oncotarget.* 2014 May 30;5(10):3012-22.
7. Shindoh J, **Kaseb A**, Vauthey JN. Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy. *Liver Cancer.* 2013 Jan;2(1):47-54.
8. Bupathi M, **Kaseb AO**, Bern-Stram F, Naing A. Hepatocellular Carcinoma: Where There Is Unmet Need Molecular Oncology. *Mol Oncol.* 2015 Oct;9(8):1501-9. 2015 Jun 25.
9. Asham EH, **Kaseb A**, Ghobrial RM. Management of Hepatocellular Carcinoma. *Surg Clin North Am.* 2013 Dec;93(6):1423-50

### Editorials

1. Odisio BC, **Kaseb AO.** Anti-angiogenic therapy in the setting of TACE: an elusive synergy? *Lancet Gastroenterol Hepatol.* 2017 Oct 4.
2. Wilson SR, Greig P, **Kaseb AO.** Pretreatment assessment of hepatocellular cancer: expert consensus conference. *HPB (Oxford)* 12(5):300-1, 6/2010. PMID: PMC2951815.
3. **Kaseb AO.** Beyond the Basics: The Differential Effects of Demographics and Hepatitis Status on Treatment Outcome in Hepatocellular Carcinoma. *Oncology* 2013;85(1):41-43.
4. **Kaseb AO.** Editorial: charting the future of hepatocellular carcinoma publications. *J Hepatocell Carcinoma* 5:51-54, 2018. e-Pub 5/2018. PMID: PMC5947843.
5. **Kaseb AO.** Grant, deny, or reassess the role of yttrium-90 in hepatocellular carcinoma? *Lancet Oncol.* 2017 Dec;18(12):1560-1561. Epub 2017 Oct 26. PMID: 29107680

### Abstracts

**ASCO Presentations by Ahmed Omar Kaseb et al.:**  
<http://ascopubs.org/action/doSearch?AllField=kaseb%2C+a>

### Books (edited and written)

1. Hepatocellular Carcinoma - Future Outlook. InTech Open Access Publisher: October, 2013. ISBN 978-953-51-1202-0. **Editor: AO Kaseb**

### Book Chapters

1. **Kaseb A**, Tejwani S. Biological Response Modifiers in Cancer Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Ed(s) Kohli K. Elsevier,

- 2006.
2. **Kaseb A**, Tejwani S. Cancer Gene Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Ed(s) Kohli K. Elsevier, 2006.
  3. **Kaseb A**, Tejwani S. Vaccines in Medical Oncology. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Ed(s) Kohli K. Elsevier Publishing Co., Inc., 2006.
  4. **Kaseb A**, Thomas M. Chemotherapy and Novel Therapies. In: Hepatocellular Carcinoma: A Practical Approach. Ed(s) Bolini L, Reddy K, Al Knawy B. Informa Health Care Publishing Co., Inc.: United Kingdom, 2008.
  5. Azmi AS, Mohammad M, **Kaseb A**, Sarkar F, Mohammad RM. Utility of Animal Models in Pancreatic Cancer Research. In: Pancreatic Cancer. Chapter 34. Springer: New York, NY, 577-599, 2008.
  6. **Kaseb A**, Thomas M, Curley S. Gall Bladder and Bile Duct Cancer. In: Holland-Frei Cancer Medicine, 8. Ed(s) Kufe DW, Frei E, Holland JF, Weichsebaum RR, Pollock RE, Bast RC, Hong WK, Hait WN. People's Medical Publishing House-USA: Shelton, CT, Part Five, Section 27; 87, 2009.
  7. **Kaseb A**, Selim Abdel-Hafez. Kalonji (Thymoquinone). In: Molecular Targets and Therapeutic Uses of Spices: Modern Uses for Ancient Medicine. Ed(s) BB Aggarwal, AB Kunnumakkara. World Scientific Publishing Co., Inc.: Hackensack, 257-280, 2009.
  8. Hassan M, **Kaseb A**. Epidemiology and Pathogenesis of Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Ed(s) K McMasters, JN Vauthey. Springer, 1, 2010.
  9. Bhadkamkar N, Javle M, Arvitscher R, Krishnan S, **Kaseb AO**. Hepatobiliary Malignancies. In: M.D. Anderson Cancer Center's Manual of Medical Oncology, 2nd. Ed(s) HM Kantarjian, RA Wolff, CA Koller. McGraw-Hill: New York, 505-528, 2012.
  10. Szklaruk J, Abdalla EK, Krishan S, **Kaseb A**, Javle M. Gallbladder/Biliary Tract. In: Oncologic Imaging: A Multidisciplinary Approach, 1<sup>st</sup> Edition. Elsevier, 2012. ISBN : 9781437722321.
  11. Szklaruk J, Abdalla EK, Krishnan S, **Kaseb A**, Javle M. Liver. . In: Oncologic Imaging: A Multidisciplinary Approach, 1<sup>st</sup> Edition. Elsevier, 2012. ISBN : 9781437722321. Editor: P Silverman
  12. **Kaseb A**, Thomas M. The Future: Combination Systemic Therapy for Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Ed(s) K McMasters, JN Vauthey. Springer, 15, 2010.
  13. **Kaseb AO** and Kaulik L. Sorafenib in the Continuum of Care for Hepatocellular Carcinoma: Challenges in Defining Optimal Practice. Chapter 11. In: Hepatocellular Carcinoma - Future Outlook. InTech Open Access Publisher: October, 2013. ISBN 978-953-51-1202-0. **Editor: AO Kaseb**

#### Letters to the Editor

1. Kaseb AO, Morris JS, Hassan MM, Abbruzzese JL. Reply to A. Goyal et al. J Clin Oncol 30(24):1019-1020, 2/2012.
2. Kaseb AO, Morris JS, Hassan MM. Reply to Shao YY et al. J of Natl Cancer Inst, 2015

#### Manuals, Teaching Aids, Other Teaching Publications

Liver cancer educational poster/brochure distributed through Texas Cancer Information (TCI): <https://www.texascancer.info/pdfs/livercancerposter.pdf>

#### EDITORIAL AND REVIEW ACTIVITIES

##### Editor/Service on Editorial Board(s)

**Editor-in-Chief**, Journal of Hepatocellular Carcinoma: 2013-Current

Senior Editor, American Journal of Clinical Cancer Research  
World Journal of Hepatology  
Disease Biomarkers

**Journal Reviewer**

Journal of Clinical Oncology  
New England Journal of Medicine  
JAMA  
Lancet  
Lancet Oncology  
Hepatology  
Gastroenterology  
GUT  
Gastroenterology and Hepatology  
Cancer  
Clinical Cancer Research  
Cancer Prevention Research  
The Oncologist  
Oncology  
Oncotarget  
Cancer Epidemiology  
Hepatology International

**TEACHING**

**Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center**

**Formal Teaching**

**Training Programs**

**Monthly Case Studies Lecture/Quiz:** Hepatocellular Carcinoma-medical oncology fellowship program at MDACC  
2007-present

**Other Formal Teaching**

**Faculty/Teacher:** Liver Tumor Study Group Weekly Tumor Conference  
2007-present

**Supervisory Teaching**

**Committees**

**Advisory Committees**

Several PhD Candidates, University of Texas

**Direct Supervision**

**Medical Students**

The University of Texas Medical School Students, The University of Texas Medical School Students

**Graduate Students**

MDACC, Department of Medical Oncology, Graduate Students:  
Mentor, The University of Texas MD Anderson Cancer Center, Neeraj Shah, MD, MPH, 1/2011-6/2011

**Postdoctoral Research Fellows**

Mentor, Ibrahim Sahin, MD, 2012-2013



Mentor, Reham Ali, MD, 2013-2017  
Mentor, Sahin Lacin, MD, 2014-2016

### **Clinical Residents and Fellows**

Mentor, The University of Texas MD Anderson Cancer Center, Apurv Varia, MD, 11/2009–12/2009

Mentor, The University of Texas Internal Medicine Program, Vikesh Khanijow, MD, 07/2010.

Mentor, The University of Texas MD Anderson Cancer Center, Young Chae, MD, 2012–2004

Mentor, Baylor College of Medicine-Internal Medicine Resident, Mehmet A. Bilen, MD, MD, 4/2012–5/2012

Mentor, The University of Texas MD Anderson Cancer Center, Marc Uemura, MD, 2014–present

Mentor, The University of Texas MD Anderson Cancer Center, Shiraj Sen, MD, 2015–present

Mentor, The University of Texas MD Anderson Cancer Center, James T Link, MD, 2015–present

Mentor, Baylor College of Medicine, Medical Oncology Fellow, Mehmet Akce, MD, 2015-Present

Mentor, The University of Texas MD Anderson Cancer Center, Roberto Carmagnani Pestana, MD, 2017–present

### **CONFERENCES AND SYMPOSIA**

**Invited as a faculty, session chair/co-chair and as a presenter (poster and oral) to dozens of national and international conferences:**

List available upon request **(included in long version of CV)**

### **Lectureships and Visiting Professorships**

List available upon request **(included in long version of CV)**

### **PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

#### **Professional Society Activities, with Offices Held**

##### **National and International**

American Society of Clinical Oncology (ASCO)  
Member, 2005–present

SWOG (Southwest Oncology Group)  
Member-Gastrointestinal Committee, 2007–present

American Association for the Study of Liver Disease (AASLD)  
Member, 2008–present

American Association of Cancer Research (AACR)  
Member, 2006–present

American College of Physicians (ACP)  
Member, 2001–present

International Liver Cancer Association (ILCA)  
Member, 2007–present

International Society of Gastrointestinal Oncology (ISGIO)  
Member, 2008–present

**Local/State**

American Society of Clinical Oncology (ASCO)-Texas Chapter  
Member, 2007–present

Texas Medical Association (TMA)  
Member, 2007–present

Harris County Medical Society (HCMS)  
Member, 2007–present  
Executive Committee Member: 2017-2018

**UNIQUE ACTIVITIES**

- 1. Tae Kwon Do Second Dan Black Belt and member of Leadership Team: Masters Tae Kwon Do; Founder and Master: George Weissfisch, USA Olympic Team Coach**
- 2. Scout Master, Boy Scouts of America, Troop 713 Houston, Texas**
- 3. Member, Order of The Arrow Society, Boy Scouts of America**

**DATE OF LAST CV UPDATE**

10/14/2019 Ahmed Omar Kaseb